A. Lazarev

Comparative efficacy and safety of prolgolimab and nivolumab in first-line therapy for metastatic or unresectable melanoma: a systematic review, matching-adjusted indirect comparison, and cost-effectiveness analysis

Background . Metastatic and unresectable cutaneous melanoma (MM/uRCM) is an aggressive malignancy associated with high mortality due to its pronounced metastatic potential. Immune checkpoint inhibitors are used to treat MM/uRCM in the Russian Federation. These inhibitors include nivolumab and prolgolimab, which...